Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Imunon Inc IMNN

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Bullboard (NDAQ:IMNN)

View:
Post by MikeTesteron Aug 01, 2024 6:33pm

IMNN: A Promising DNA-Based Immunotherapy and Vaccine Platfo

https://beyondspx.com/2024/08/01/imnn-a-promising-dna-based-immunotherapy-and-vaccine-platform/
Post by Iseneschalon Jul 30, 2024 9:09am

IMNN....$75 mil Shelf on file EDGAR

Don't get greedy is my advice ; ) ......currently at $3.60 in PM trading. Cheers ! Here is the EDGAR S3 filing: sec.gov/Archives/edgar/data/749647/000149315224019876/forms-3.htm
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities